Gennao Bio, a genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, appointed    Christopher Duke, chief executive officer. Duke succeeds executive chairman and founding chief executive officer, Stephen Squinto, who will become a scientific advisor. “Chris has made significant contributions to the growth of Gennao since its inception in 2020, demonstrating strong leadership and strategic agility,” Julie Hambleton, independent member of Gennao’s ...